2019 American Transplant Congress
Preoperative Marginal Factors Do Not Affect the Medically Complex Living Donors for Kidney Transplantation
Nagoya Daini Red Cross Hospital, Nagoya Aichi, Japan
*Purpose: Recently, medically complex living donors with marginal factors including hypertension, dyslipidemia, glucose intolerance, and obesity are increasing. The impact of preoperative marginal factors on…2019 American Transplant Congress
Utilization of Hepatitis C Donors is Safe and Cost Effective
*Purpose: The use of hepatitis C (hep C) positive donors has become increasingly attractive with the advent of improved curative pharmacologic treatments. As a result…2019 American Transplant Congress
Long-Term Survival after Kidney-Pancreas Transplantation: Lessons from World Largest Series of Long-Term Survivors
University of Wisconsin, Madison, WI
*Purpose: Since 1983, more than 1700 patients have undergone pancreas transplant, mainly as a simultaneous-kidney-pancreas transplant (SPK) at our center. Forty-eight SPK recipients have pancreas…2019 American Transplant Congress
Non-Invasive Monitoring of the Kidney Allograft
*Purpose: A major issue in kidney transplantation is the lack of validated non-invasive biomarkers for monitoring graft function, current biochemical markers (i.e., creatinine) have poor…2019 American Transplant Congress
Hypertrophy Prediction Model for Contralateral Kidney after Living Donation
*Purpose: Compensation of contralateral kidney function is well established and many factors have been proposed as risk factors. There is no prediction model to estimate…2019 American Transplant Congress
Belatacept Based CNI Free Immunosuppression in Pancreas Transplantation. Results at 4 Years
Indiana University School of Medicine, Indianapolis, IN
*Purpose: CNI based Immunosuppression is a well known risk factor for worsening renal function. We report our experience in converting Pancreas Transplant recipients from tacrolimus…2019 American Transplant Congress
Monitoring Inflammatory Cytokine Levels in Kidney Transplant Patients (KTx Pts) with Chronic Antibody Mediated Rejection (cABMR) Treated with Clazakizumab (CLZ, Humanized Anti-IL-6 Monoclonal Antibody)
*Purpose: IL-6 is a pro-inflammatory cytokine involved in KTx rejection. A clinical trial to improve cABMR using CLZ in HLA-sensitized KTx Pts is underway. Inhibition…2019 American Transplant Congress
The Outcomes of Living Donor Kidney Transplantation in Donors or Recipients with Donors’ Renal Arteriosclerotic Lesions on Preoperative Computed Tomography
*Purpose: Living donor kidney transplantation is being increasingly performed with elderly donors. Such elderly donors often have arteriosclerotic lesions (AS) (Figure 1). Whether the outcomes…2019 American Transplant Congress
The Use of dd-cfDNA as a Predictive Tool for Outcome Decreased Kidney Function
*Purpose: A decline in estimated glomerular filtration rate (eGFR) during the first 12 months following kidney transplantation is associated with poor outcome and increased graft…2019 American Transplant Congress
Change in Estimated Glomerular Filtration Rate and Risk of Allograft Failure in Patients Diagnosed with Active Antibody-Mediated Rejection Following Kidney Transplantation
*Purpose: There are challenges in designing an adequate and well-controlled study of patients with active antibody-mediated rejection (ABMR), especially in the absence of a valid…
American Transplant Congress abstracts